Top Markets
Coin of the day
Bio-Path Holdings, Inc. Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc.

BPTH
Classifica tra le azioni #39844
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on... Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Prezzo delle azioni
$0.035
Ultima sincronizzazione: 2026-08-13
Capitalizzazione di mercato
$326.98K
Variazione (1 giorno)
-12.50%
Variazione (1 anno)
-74.55%
Paese
US
Scambia Bio-Path Holdings, Inc. (BPTH)

Categoria

EPS per Bio-Path Holdings, Inc. (BPTH)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Bio-Path Holdings, Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Bio-Path Holdings, Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE